Drug, bio-affecting and body treating compositions inventions 10/07

20070248557 - Mild leave-on composition: The present invention relates to a leave on companion animal composition having a composition having a Total Lather Volume of from about 300 ml to about 700 ml, IL1α of from about 0 pg/ml to about 7000 pg/ml, and Friction Coefficient of from about 1.2 to about 2.0.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248561 - Water-soluble polymers and their use in cosmetic and pharmaceutical preparations: e

20070248564 - Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia: This invention relates to a stable, sorbitol free suspension formulation of sodium polystyrene sulfonate.... Agent: Pearne & Gordon LLP

20070248567 - Protein crosslinkers, crosslinking methods and applications thereof: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.... Agent: Dardi & Associates, PLLC

20070248534 - Auger effect-based cancer therapy method: A method for the treatment of a tumor, comprising administering to a subject a therapeutically effective amount of a complex of a heavy element with a polydentate, pyrrole-containing macrocyclic ligand substituted with charged chemical groups, wherein said complex is capable of bringing said heavy element into close proximity to the... Agent: Nixon & Vanderhye, PC

20070248533 - Stabilized and lyophilized radiopharmaceutical agents for destroying tumors: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal... Agent: Brooke Schumm Iii

20070248539 - Agrm2 antigen: The antigen recognized by the antibody produced by a deposited cell line (ATCC accession no. PTA 5411) has been shown to be a fragment of vimentin. This vimentin fragment will be useful in therapy of and screening for cell proliferative disorders such as cancer.... Agent: Wilson Sonsini Goodrich & Rosati

20070248537 - Compositions and methods for cellular imaging and therapy: The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N4 compounds and derivatives.... Agent: Fulbright & Jaworski L.L.P.

20070248538 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic... Agent: Mchale & Slavin, P.A.

20070248535 - Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity: The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and... Agent: Wilmerhale/columbia University

20070248536 - Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography: The present invention relates to conjugates containing a covalent linkage between one or more polypeptide molecules based on gamma-crystallin or ubiquitin and one or more functional components. Furthermore, the present invention relates to a method for the preparation of such a conjugate as well as to the use of the... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070248540 - Biochemical methods for measuring metabolic fitness of tissues or whole organisms: The present invention relates to biochemical methods for assessing metabolic fitness and/or aerobic demands of a living system. Specifically, the rate of synthesis and turnover of the molecular components of mitochondrial mass are used to determine the aerobic capacity and/or aerobic demand of tissues or living organisms. The direct measurement... Agent: Morrison & Foerster LLP

20070248543 - Chicken deoxycytidine and deoxyadenosine kinase enzymes and their use: The application relates to the field of suicide gene therapy using expression vectors encoding a deoxynucleotide kinase capable of converting prodrugs into cytotoxic drugs. In particular, Chicken deoxycytidine kinase and eukaryotic deoxyadenosine kinase polypeptides and nucleotides encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are... Agent: Birch Stewart Kolasch & Birch

20070248542 - Devices and methods for individualized detection of nutrient imbalance via olfactory system: A method of detecting an imbalance of nutrients in an individual is disclosed. The method comprising administration of a smell test, wherein the smell test comprises one or more support members and one or more nutrients that are aroma-intensified and incorporated into one or more support members, the method further... Agent: Law Offices Of Khalilian Sira, LLC

20070248541 - Liposome: According to the present invention, a liposome encapsulating a water-soluble substance in an internal cavity of the liposome and having a liposome particle size of 300 nm or less can be easily prepared.... Agent: Leydig Voit & Mayer, Ltd

20070248544 - Mullerian inhibiting substance levels and ovarian response: Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female response... Agent: University Of Medicine And Dentistry Of New Jersey Office Of Patents And Licensing

20070248545 - Use of the receptor gpr86: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino... Agent: Frommer Lawrence & Haug

20070248547 - Cascade macromolecular contrast agents for medical imaging: The present invention provides macromolecular contrast media for diagnostic imaging modalities.... Agent: Morgan, Lewis & Bockius, LLP

20070248546 - Clinical algorithm for excluding patients identified in virtual imaging: Aspects of the invention relate to clinical triage protocols for screening a patient population using virtual imaging techniques, for example, virtual colonoscopy. Methods for increasing the specificity of a virtual imaging procedure are provided. In aspects of the invention, colonic effluents are analyzed using one or more molecular detection assays.... Agent: Wolf Greenfield & Sacks, P.C.

20070248548 - Stable hydroalcoholic oral spray formulations and methods: Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a... Agent: Dickstein Shapiro LLP

20070248549 - Water-soluble pharmaceutical compositions of hops resins: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions... Agent: Thorpe North & Western, LLP.

20070248550 - Cosmetic emulsions containing uncoated silicone elastomers and non silicone treated pigments: Disclosed are cosmetic compositions in the form of an emulsion that contain an uncoated silicone elastomer, a solvent for the elastomer, a non-silicone treated pigment and an emulsifier, methods of making the compositions, and methods of applying the compositions to a keratinous substrate or tissue.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070248553 - Consumer noticeable improvement in wetness protection: Antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (c) from about 10% to about 99% by weight of the composition, of an... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248552 - Consumer noticeable improvement in wetness protection using solid antiperspirant compositions: Anhydrous, solid antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (c) from about 10% to about 99% by weight of the composition,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248551 - Use as an antiperspirant agent of a flocculating water-soluble polymer; cosmetic process for treating perspiration: The present invention relates to the use of a flocculating water-soluble polymer comprising amine groups borne by a side substituent directly attached to the main chain, as an antiperspirant active agent in a cosmetic composition and particularly in a cosmetic composition not containing any antiperspirant aluminum and/or zirconium salts. The... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248556 - Administration of c-glycoside compounds for activating and regulating cutaneous immunity: e

20070248555 - Composition and method for managing redness of skin associated with dermatological condition: The present invention is directed towards a topical composition for managing redness of skin associated with a dermatological condition, comprising water, gelled ethyl alcohol (an anti-bacterial), anti-oxidants, thickening agents, emulsifiers, stabilizers, and a natural esterified anti-inflammatory (Hepes). This combined therapy is more effective than anti-bacterial agents alone and is particularly... Agent: H. Jay Spiegel - H. Jay Spiegel & Associates

20070248558 - Hair styling composition in the form of a microemulsion: The compositions of the present invention relate to improved hair styling compositions in the form of microemulsions which are non-fluid and clear or transparent and which are comprising 20% to 60% by weight water; at least 3% by weight of an oil phase comprising liquid hydrophobic oils, at least 20%... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248559 - Use of a complex nutritional base in cosmetics, in particular for the hair: The invention concerns a non-therapeutic treatment of the hair and/or the scalp for men and women, wherein it consists in locally applying at the surface of the scalp a complex nutritional base in aqueous medium, comprising at least one fraction of amino acids, one fraction of water soluble vitamins, one... Agent: The Firm Of Hueschen And Sage

20070248560 - Cosmetic product comprising at least one cyanoacrylate monomer and at least one non-ionic polyurethane: Disclosed herein is a cosmetic product for treating keratin fibers, for example, human keratin fibers such as the hair, comprising at least one polymerizable cyanoacrylate monomer, and at least one non-ionic polyurethane, wherein the at least one polymerizable cyanoacrylate monomer and the at least one non-ionic polyurethane may be present... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248554 - Hair style control agent: wherein R2 represents a linear or branched alkyl group having 8 to 18 carbon atoms, and n represents an integer of 1 to 25. The first hair style control agent of the present invention may permanently straighten naturally curly/unruly hair, without damaging or providing a dry feeling to the hair.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070248562 - Stable multiphase composition comprising alkylamphoacetate: The multiphase personal care composition of the present invention comprises a first phase and a second phase. The first phase is comprised of structured surfactant phase that comprises at least about 0.5% of alkylamphoacetate. The alkylamphoacetate comprises a Percentage Diacetate of less than about 15%.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248563 - Skin care compositions including marine extracts: Skin care products, such as depilatories and epilatories, including marine extract blends are provided. The skin care products include one, two, or more of the following marine extracts, in any combination: Enteromorpha Compressa extract, Fucus Vesiculosus extract, Porphyra Umbilicalis extract, Undaria Pinnatifida extract, and Lithothamnium Calcareum extract.... Agent: Fish & Richardson P.C.

20070248565 - Pharmaceutical preparations comprising corticosteroids and antiinfective agents: The invention consists of a stable preparation of a combination drug, comprising of an anti-inflammatory agent and an anti-infective agent. The anti-inflammatory agent in this invention is a corticosteroid, and the anti-infective agent is a derivative of quinolone, amino-glycoside or their pharmaceutically acceptable salts. The combination drug essentially comprises of... Agent: Merchant & Gould PC

20070248566 - Antimicrobial polyisocyanate and derivatives thereof: The present invention discloses an antimicrobial polyisocyanate and derivatives thereof, wherein a quaternary amine is added into the polymerization reaction of a polyol and a NCO-containing isocyanate/poly-isocyanate to form the antimicrobial polyisocyanate; then, the antimicrobial polyisocyanate is added into a functional resin to form an antiseptic material. As the bactericide... Agent: Birch Stewart Kolasch & Birch

20070248568 - Aqueous wildlife attractant, cover scent, and browse supplement: Wildlife enthusiasts and hunters use attractants to increase their chances of being in the presence of desirable wildlife at a designated location. Enthusiasts and hunters use cover scents to mask the human odor thereby helping to prevent scaring the desired wildlife from a designated location. Enthusiasts and hunters use browse... Agent: Williams Family Law Firm, L.L.C.

20070248569 - Eye-drop vaccine containing copolymer 1 for therapeutic immunization: The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070248571 - Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus: An ejection liquid capable of being stably ejected based on a system using thermal energy even if the liquid contains at least one selected from the group consisting of proteins and peptides, and a method and an apparatus for ejecting the liquid containing at least one selected from the group... Agent: Fitzpatrick Cella Harper & Scinto

20070248572 - Method for treating diseases with omega interferon: A method of treating an immunologic, proliferative, or infectious disease in a warm-blooded animal is disclosed. The method comprises administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal, which dosage and activity for... Agent: Barbara G. Mcclung, Esq. Vice President General Counsel And Corporate Secretary

20070248570 - Pharmaceutical compositions containing platinum complexes with secondary xanthates and therapeutic uses thereof: Described are platinum complexes with secondary xanthates and therapeutic uses thereof for treating tumors and autoimmune diseases.... Agent: Klauber & Jackson

20070248580 - Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue: Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that... Agent: Moore & Van Allen PLLC

20070248578 - Mrna transfected antigen presenting cells: A method of amplifying RNA to obtain RNA molecules that are predominantly in the sense orientation and essentially devoid of RNA molecules that are in the anti-sense orientation. A method of transfecting antigen presenting cells with a composition comprising sense RNA encoding immunogenic antigens and essentially devoid of antisense RNA... Agent: Merix Bioscience, Inc.

20070248579 - Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome: This invention relates to the use of secreted SF01-SF13 proteins, to the use of polynucleotides encoding these, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes mellitus), obesity and/or metabolic syndrome and to the use in regeneration of tissues such... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070248581 - Mgra is a redox regulator of antibiotic sensitivity and virulence: The present invention relates to the identification of a specific cysteine (Cys) residue in MgrA of Staphylococcus aureus and homologs in other bacteria that acts as a redox switch to regulate virulence of S. aureus and expression of bacterial genes that confer resistance to antibiotics. In addition, MgrA is found... Agent: Fulbright & Jaworski L.L.P.

20070248582 - Lactic bacteria and their use in the prevention of diarrhea: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourista”. The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492 Lactobacillus casei and a mixture... Agent: Godfrey & Kahn S.c.

20070248583 - Novel strains belonging to the genus paenibacillus and method of controlling plant disease by using these strains or culture thereof: Novel strains Paenibacillus sp. BS-0048, Paenibacillus sp. BS-0074, Paenibacillus polymyxa BS-0105 and Paenibacillus sp. BS-0277 and Fusaricidin A, Fusaricidin B and novel compounds 3 and 4 produced thereby have an activity of inducing resistance to plant diseases. Thus, they can protect plants from infections with fungi, bacteria, viruses and so... Agent: Sughrue Mion, PLLC

20070248573 - Chimeric bacteriophages, chimeric phage-like particles, and chimeric phage ghost particles, methods for their production and use: The objective of the present invention is to provide chimeric phage-derived particles, that may be used as safe food grade vehicles to for presenting various factors (e.g. antigens, virulence proteins, receptors, ligands, etc.) for living cells. In addition to at least one normal phage or virus component the particles comprise... Agent: Nixon & Vanderhye, PC

20070248575 - Bone graft composition: The invention provides methods of making a bone graft composition. Also featured are methods of treatment using the bone graft composition and articles of manufacture that include the bone graft composition.... Agent: Fish & Richardson P.C.

20070248577 - Methods and compositions for administering stem cells: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the... Agent: Biotechnology Law Group C/o Portfolioip

20070248574 - Methods of making and using skin-derived stem cells: The present invention describes a method for isolating skin derived precursor stem cells from hair follicles or dermal papillae and also describes the use of these cells for inducing hair growth.... Agent: Clark & Elbing LLP

20070248576 - Regulation of the serotonin reuptake transporter and disease: Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus,... Agent: Viksnins Harris & Padys Pllp

20070248584 - Immunomodulating compositions, uses therefore and processes for their production: The present invention relates to the use of at least one set of peptides in compositions and methods for modulating an immune response to one or more polypeptide antigens. In certain embodiments, the sequences of a respective set of peptides are derived in whole, or in part, from a single... Agent: Proskauer Rose LLP

20070248585 - Methods of regulating renalase (monoamime oxidase c): The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070248586 - Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same: Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also... Agent: Sheridan Ross PC

20070248587 - Wet wipes including a composition for reduction and prevention of wrinkles on the skin: Wet wipes comprising a composition for reducing and preventing wrinkles on the skin is disclosed. The composition is provided in the form of an aqueous composition comprising containing papain, urea, boric acid, preservatives, the sodium salt of 2-pyrrolidone-5-carboxylic acid, and almond extract.... Agent: Gordon & Rees LLP

20070248593 - 32 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070248592 - Agent for inhibiting proliferation of neural stem cells: The object of the present invention is to provide methods for inhibiting proliferation of neural stem cells, an agent for inhibiting proliferation of neural stem cells, and methods for using the same. According to the method of the present invention, a galectin-1 inhibitor such as anti-galectin-1 antibody and/or an integrin... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248594 - Cxcr1 and cxcr2 chemokine antagonists: e

20070248590 - Modulators of cdc2-like kinases (clks) and methods of use thereof: Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070248588 - Novel compositions and methods for the treatment of immune-related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20070248591 - Preventive/therapeutic drug for arteriosclerosis: The present invention provides preventive/therapeutic agents for arteriosclerosis, diabetes mellitus, etc., which comprise glucosylceramide or (and) lactosylceramide synthase inhibitors, expression inhibitors for glucosylceramide or (and) lactosylceramide synthase genes, methods and kits for screening the preventive/therapeutic agents, and so on.... Agent: Foley And Lardner LLP Suite 500

20070248589 - Spatial for altering cell proliferation: This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an... Agent: Klarquist Sparkman, LLP

20070248595 - Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy: The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.... Agent: Baker Botts L.L.P.

20070248596 - Transgenic ficus, method for producing same and use thereof: The present invention relates to transgenic Ficus plants, particularly Ficus carica (fig tree), to a method for producing same, and to Ficus plants, plant materials and plant products produced by or from such genetically modified plant material. More specifically, the present invention relates to transgenic Ficus carica plants and use... Agent: Martin D. Moynihan Prtsi, Inc.

20070248600 - Glycosylated antibodies: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1%... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070248597 - Methods of decreasing vascular calcification using il-1 inhibitors: The present invention relates to methods of decreasing, inhibiting, or preventing vascular calcification in subjects by administering IL-1 inhibitors. IL-1 inhibitors useful in this invention include anakinra, IL-1 antibodies, IL-1 RI antibodies, IL-1 trap molecules, soluble IL-1 receptors, and anti-IL-1/IL-1R peptides and peptibodies.... Agent: Amgen Inc.

20070248598 - Recombinant anti-vla4 antibody molecules: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites... Agent: Fish & Richardson

20070248599 - Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor: Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide (Aβ) in the brain. Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretases. Apolipoprotein E receptor 2 (ApoER2) is a cell-surface receptor for apolipoprotein E. This study shows that ApoER2 interacts with X11α/β proteins and that... Agent: Fulbright & Jaworski L.L.P.

20070248602 - Fc variants having increased affinity for fcyrllc: The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070248603 - Fc variants with increased affinity for fcyrlla: The present invention relates to Fc variants having increased affinity for FcγRIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070248601 - Non-human transgenic mammal for the constant region of the class a human immunoglobulin heavy chain and applications thereof: The invention relates to a non-human transgenic mammal with an IgH locus modified by replacement of the switching sequence S?, with all or part of a transgene comprising the gene Cα of a class A human immunoglobulin, including at least the exon, coding for the CH3 domain and the membrane... Agent: Lowe Hauptman Ham & Berner, LLP

20070248604 - Anti-fgf19 antibodies and methods using same: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.... Agent: Genentech, Inc.

20070248605 - Fibroblast growth factor receptors 1,2,3, and 4 as targets for therapeutic intervention: A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248606 - Treatment of alzheimer's disease: The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with... Agent: Young & Thompson

20070248607 - Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells: The present invention relates to methods of treating immune disorders, particularly autoimmune diseases and cancers having an immune-deficient aspect involving NKG2D-positive CD4+ cells. In addition, the invention provides screening methods that assess the ability of compositions to modulate the negative immunomodulatory effects of NKG2D-positive CD4+ cells. Also provided is a... Agent: Fulbright & Jaworski L.L.P.

20070248608 - Monoclonal antibodies to progastrin: The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin and the hybridomas that produce these MAbs. Also... Agent: Fish & Richardson, PC

20070248610 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20070248611 - Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist: This invention relates to methods for treating unwanted body weight loss (such as with cachexia and with aging), eating disorders (such as anorexia nervosa), or opioid-induced emesis by peripheral administration of a trkB agonist. The invention also relates to compositions and kits comprising a trkB agonist.... Agent: Pfizer Inc.

20070248609 - Therapeutic method: The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the... Agent: Scully Scott Murphy & Presser, PC

20070248612 - Isolated plasma and method for hyperimmunisation and plasma collection: The present invention relates to isolated canine animal plasma, a method for isolating canine animal plasma, plasma obtained form an immunised or hyperimmunised canine animal and treating a canine animal with the isolated canine animal plasma. The method includes the step of selecting a canine animal having a blood group... Agent: Hoffmann & Baron, LLP

20070248613 - Human antibodies interacting with hiv gp41: Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which... Agent: Merck And Co., Inc

20070248615 - T helper cell epitopes: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of SSKTQTHTQQDRPPQPS (SEQ ID NO: 1); QPSTELEETRTSRARHS (SEQ ID NO: 2); RHSTTSAQRSTHYDPRT (SEQ... Agent: Nixon & Vanderhye, PC

20070248614 - Vaccination: The present invention relates to the use of a 1H-imidazo[4,5-c]quinolin-4-amine derivative as an adjuvant for use with nucleic acid vaccination.... Agent: Glaxosmithkline Corporate Intellectual Property

20070248616 - Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and... Agent: Knobbe Martens Olson & Bear LLP

20070248617 - Medical uses of carrier conjugates of non-human tnf -peptides: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising—a VLP and a particular peptide derived from a polypeptide from the TNF-superfamily linked thereto for use in the production of vaccines for the treatment of autoimmune... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070248618 - Tat-based vaccine compositions and methods of making and using same: A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070248619 - New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use: The present invention relates to a new pharmaceutical composition from natural materials belonging in traditional Chinese medicine and to its preparation method. Said new pharmaceutical composition comprises Astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf. At first, astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf are... Agent: Andrews Kurth LLP Intellectual Property Department

20070248620 - Method of treating malignancies and viral infections and improving immune function with a dietary supplement: Provided herein is a dietary supplement comprising as its active ingredients soybean, mushroom and mung bean is used in a method to treat non-small cell lung carcinoma (NSCLC). The active components of the dietary supplement include phytoestrogens, β-glucans, saponins, inositol hexaphosphate, and lectins.... Agent: Morrison & Foerster LLP

20070248621 - Food product containing policosanols: The invention provides a novel composition and method for reducing “bad” cholesterol and increasing “good” cholesterol. The composition of the invention comprises a food product having sugar cane juice. The sugar can juice preferably contains policosanols. A method of preventing or treating cardiovascular disease comprising administering a composition comprising sugar... Agent: Occhiuti Rohlicek & Tsao, LLP

20070248622 - Attenuated francisella bacteria: In one embodiment, there is disclosed a method of inducing an immune response in a subject comprising administering to the subject a Francisella bacterium that includes an alteration in the nucleic acid sequence encoding the mglA, iglA, iglB, iglC, or iglD gene of the bacterium.... Agent: Fulbright & Jaworski L.L.P.

20070248623 - Gene construction, vector and dna vaccine for the vaccination of aquatic animals: The gene construct comprises a nucleic acid sequence that encodes an immunogenic peptide of an aquatic animal pathogen under the control of an expression control sequence that can direct the expression of said immunogenic peptide in an aquatic animal and which comprises the sequence of a cytomegalovirus (CMV) promoter joined... Agent: Ostrolenk Faber Gerb & Soffen

20070248624 - (1,10b-dihydro-2-(aminocarbonyl-phenyl)-5h-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors: The present invention relates to 5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as inhibitors of the viral replication of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present HIV inhibitors with other anti-retroviral... Agent: Philip S. Johnson Johnson & Johnson

20070248625 - Peptide originating from vaccinia virus: A vaccine for preventing or treating Orthopoxvirus infection that induces a protective or therapeutic immune response, wherein the vaccine comprises (1) an amino acid sequence of 20 amino acid or less (preferably 12 amino acid or less and most preferably 11 amino acid or less) of the formula X1-SEQ ID... Agent: Quarles & Brady LLP

20070248626 - Recombinant toxin fragments: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070248627 - Gene therapy for tumors using minus-strand rna viral vectors encoding immunostimulatory cytokines: The present invention provides methods for treating tumors, which comprise the step of administering into tumor sites a minus-strand RNA viral vector encoding an immunostimulatory cytokine or cells introduced with the vector. The present invention also provides compositions for treating tumors, which comprise as an active ingredient the minus-strand RNA... Agent: Clark & Elbing LLP

20070248628 - Immunogens in cancer stem cells: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially cancer stem cells. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer cells, especially cancer stem cells.... Agent: Lorraine H. Keller Immunotope Inc.

20070248629 - Pharmaceutical formulations for iontophoretic drug delivery: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of acyclovir (ACV) to at least one target tissue. The present invention also provides methods of treating viral infection in at least one target tissue of a patient by iontophoretically delivering a formulation of the invention... Agent: Elmore Patent Law Group, PC

20070248630 - Pharmaceutical formulations for iontophoretic methotrexate delivery: Pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of methotrexate to at least one target tissue are described and methods for administering methotrexate via iontophoresis.... Agent: Elmore Patent Law Group, PC

20070248633 - Compositions containing a hydroxylated diphenylmethane compound, methods of use: where formula variables are defined in the body of the application and claims and (b) at least one ingredient promoting the solubilization, stabilization and/or activity of the hydroxylated diphenylmethane compound of formula (I). The invention also relates to a cosmetic method for caring for or making up the skin, comprising... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070248631 - Cosmetic composition and cosmetics: Liquid cleansing oils capable of mixing well with old makeup and being easily rinsed off with water have come into the mainstream in recent years. An object of the present invention is to provide a cosmetic composition which easily mixes with old makeup, enables the old makeup to be lifted... Agent: Wood, Herron & Evans, LLP

20070248634 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248632 - Highly concentrated self- emulsifying emulsion bases used for the production of oil-in-water emulsions: Emulsions suitable for use in cosmetic and pharmaceutical compositions are disclosed. Various substrates for body care, such as wipes and pads, are disclosed, which substrates are impregnated with the emulsions. Such treated substrates are suitable for use, for example, in body care, sun protection, antiperspirant and insect repellent formulations. A... Agent: Cognis Corporation Patent Department

20070248635 - Green tea jewelry: A method for making green tea jewelry is provided. The jewelry may be worn as a transdermal source of green tea components used as an alternative to or in addition to ingestion of green tea liquid or solids. Also provided is a kit for providing green tea jewelry in a... Agent: MastermindIPLaw PC

20070248636 - Method for achieving increased effectiveness when using a synthetic pheromone composition to cause mating disruption among insect pests: A method for achieving increased effectiveness when using a synthetic pheromone composition to cause mating disruption among insect pests such as the navel orangeworm. Makes use of automated dispensers such as aerosol dispensers strategically placed throughout and area of treatment such as an orchard or field and configured to initiate... Agent: Dalina Law Group, P.C.

20070248638 - Structurally modified acellular tissue engineering scaffolds and methods of production: Methods are provided for producing a bioscaffold from natural tissues by oxidizing a decellularized tissue to produce a bioscaffold having pores therein. The pore size and porosity is increased to better accommodate intact cells so that live cells can better infiltrate and inhabit the bioscaffold. The bioscaffold may be freeze-dried... Agent: Myers Bigel Sibley & Sajovec

20070248637 - Bioactive agent release coating and controlled humidity method: A coating composition in the form of a one or multi-part system, and method of applying such a composition under conditions of controlled humidity, for use in coating device surfaces to control and/or improve their ability to release bioactive agents in aqueous systems. The coating composition is particularly adapted for... Agent: Surmodics, Inc.

20070248642 - Foam and use thereof: forming a dispersion by mixing i) a solution comprising a soluble polysaccharide and a plasticizer and adding a polysaccharide/gel-forming ion particles or ii) a soluble, preferably immediately soluble, polysaccharide, preferably an alginate, a polysaccharide/gel-forming ion particles, and adding a solvent, said dispersion (ii) further comprising a water soluble plasticizer to... Agent: Patent Administrator Fmc Corporation

20070248639 - Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures: Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing... Agent: Marcia S. Kelbon, Esq. Omeros Corporation

20070248640 - Occlusive implant and methods for hollow anatomical structure: Apparatus and methods for treating a hollow anatomical structure comprises an implant sized for insertion into a hollow anatomical structure. The implant comprises a plurality of loose, bulked fibers. The fibers are formed from one or more bioabsorbable materials. Upon implantation, the apparatus causes a partial occlusion of the hollow... Agent: Knobbe Martens Olson & Bear LLP

20070248643 - Polymerizable emulsions for tissue engineering: Provided are biocompatible viscoelastic solid materials derived from polymerization of fluid water-in-oil emulsions, along with methods of their preparation and methods for their use for tissue engineering applications, including for reforming diseased, damaged or degenerated intervertebral discs by acceptably non-invasive means.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20070248641 - Use of del-1 in hair, bone and cartilage regeneration: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells,... Agent: Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.L.P.

20070248644 - Muller stem cells: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070248645 - Ophthalmic oil-in-water type emulsion with stable positive zeta potential: An ophthalmic oil-in-water type emulsion, which includes colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent, at least one no ionic surfactant, the emulsion having a positive zeta potential and meeting zeta potential stability Test A requirements. Process for making... Agent: Young & Thompson

20070248646 - Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage: Provided are methods for alleviating a symptom of an eye condition by administering to a mammal an amount of azurocidin inhibitor effective to alleviate the symptom of the eye condition.... Agent: Goodwin Procter LLP Patent Administrator

20070248649 - Carbohydrates mixture: A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large... Agent: Bacon & Thomas, PLLC

20070248647 - Erythritol suppression of ghrelin: The present invention provides novel means to make a new food, especially as a result of cooking or baking but also with cold food preparation to dilute the fat in such foods. This new food is the result of eliminating sugar and independent flour in pastry by mixing erythritol and... Agent: Keith E. Kenyon, M.d.

20070248650 - Food products comprising long chain polyunsaturated fatty acids and methods for preparing the same: The present invention includes a food oil composition comprising a blend of a first oil comprising an LC PUFA and a second oil comprising substantially no LC PUFA. The first oil can preferably comprise an omega-3 LC PUFA, an omega-6 LC PUFA or mixtures thereof. The present invention also provides... Agent: Sheridan Ross PC

20070248648 - High protein, fatigue reducing powder: A powdered composition which provides improved muscle growth and helps reduce fatigue, comprising a combination of edible nutritional whey protein, citrulline malate, and at least one branched chain amino acids. The branched chain amino acids are L-isoleucine, L-leucine, and L-valine. The concentration of nutritional protein present in the composition ranges... Agent: Shirley L. Church, Esq. Duckor Spradling Metzger & Wynne

20070248651 - Formulation for treatment of acne: A vitamin, mineral, herbal, and micronutrient treatment for acne via support of the physiologic processes in the body which cause acne is disclosed. It is a targeted formula, designed specifically to address the causes of acne. This specific, unique formulation preferably in a gummy substrate for ease of administration, to... Agent: Thomas M. Freiburger

20070248652 - Nutritional food and feed, compostition, processing and method of use: The present invention relates to means for protecting and incorporating bioactive compounds in food or feed formulations used to enhance the health status and growth performance of human and non-human organisms.... Agent: Martin D. Moynihan Prtsi, Inc.

20070248653 - Hemostatic compositions and methods for controlling bleeding: The disclosure provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions include an article containing cellulose, e.g., cotton gauze, and a cross-linked polysaccharide ionically linked to the cellulose. Methods of making and using the hemostatic compositions are also provided.... Agent: Fish & Richardson P.C.

20070248656 - Topical preparation dispensers and methods of using the same: Topical preparation dispensers and methods of using the same are provided. Aspects of the invention include a topical preparation dispenser having a holder, one or more vertically stacked topical preparations in the holder, and a cap at one end of the holder configured such that upon movement of the cap,... Agent: Bozicevic, Field & Francis LLP

20070248655 - Lenticular shaped protective mouth sore discs: An adherent, soluble oral patch for delivering topical medication in the mouth having a lenticular shape. The structure of the oral patch is formed with a material that remains solid at human mouth temperatures and slowly dissolves or erodes in saliva, such as a network of long molecules such as... Agent: Graybeal, Jackson, Haley LLP

20070248654 - Protective mouth sore discs made with corn starch: An adherent, soluble oral patch for delivering topical medication in the mouth made with corn starch which remains solid at human mouth temperatures and slowly dissolves or erodes in saliva and is hydrophilic.... Agent: Jeffrey T. Haley Graybeal Jackson Haley LLP

20070248657 - Multi-compartment transdermal pain control device: Multi-compartment patches containing skin-permeable forms of pharmaceutically effective amounts of an opioid agonist, an NMDA receptor antagonist and an anti-inflammatory are useful for the transdermal delivery of the active ingredients to alleviate pain.... Agent: Knobbe Martens Olson & Bear LLP

20070248658 - Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers: The subject of this application is the use of film-forming polyurethanes that are used in hair care agents or mixtures of these polyurethanes with other polymers in pharmaceutical preparations for dermal or transdermal administration of active ingredients, as well as patches and pharmaceutical preparations that contain these hair care polyurethanes.... Agent: Millen, White, Zelano & Branigan, P.C.

20070248659 - Individualized cancer therapy: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue... Agent: Bryan Cave LLP

20070248660 - Method for treating warm-blooded vertebrates with halide-free glucosamine-acidic drug complexes: A method of treating a warm-blood vertebrate. The vertebrate may be a human being or a lower animal. The treatment method involves administering to the vertebrate in need of such treatment a pharmaceutically effective amount of a complex of halide-free glucosamine and a therapeutic drug having a pKa of less... Agent: Law Offices Of Jack Matalon

20070248661 - Capsule for releasing agents contained therein at defined points in a body: A capsule is capable of releasing at least one agent that is contained therein by heating at least one heating element under the effect of at least one alternating magnetic field at a defined point in a body, said capsule dissolving when entering in contact with a dissolving liquid. The... Agent: Jordan And Hamburg LLP

20070248662 - Utilization of dialkylfumarates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec / Finnegan Henderson, LLP

20070248663 - Utilization of dialkylfumerates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec / Finnegan Henderson, LLP

20070248664 - Oral antimicrobial pharmaceutical compositions: The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.... Agent: Darby & Darby P.C.

20070248665 - Compositions comprising co-precipitate of eplerenone and a water-soluble excipient: Solid compositions for oral administration comprising a co-precipitate of eplerenone and a water-soluble excipient.... Agent: Nixon & Vanderhye, PC

20070248666 - Granules comprising a beta-lactam antibiotic: The present invention relates to granules comprising a β-lactam antibiotic, wherein CH2S(72h)<50 μl of H2S gas per kg of β-lactam antibiotic, wherein CH2S(72h) is the volume of H2S gas above said granules per kg of said β-lactam antibiotic, when a sample of between 3.5 and 4.5 g of said granules... Agent: Nixon & Vanderhye, PC

20070248668 - Pharmaceutical compositions and uses thereof: The invention features pharmaceutical compositions including rifalazil, a surfactant, and a lipophilic antioxidant and methods of use thereof.... Agent: Clark & Elbing LLP

20070248667 - Tannate compositions and methods of use: Compositions comprising an opiate tannate such as, but not limited to, hydrodocone tannate or codeine tannate, alone or in combination with one or more additional active ingredients from the antihistamine, decongestant, expectorant, and/or antitussive categories which are effective when administered orally for the symptomatic relief of cough associated with respiratory... Agent: Sutherland Asbill & Brennan LLP

20070248670 - Tolterodine beads: Controlled release tolterodine beads are formed of a sugar core, an innermost sealcoat layer comprising HPMC, a tolterodine drug layer, and an outer control release layer. The thickness of the hydrophilic HPMC sealcoat layer can be used help modulate the release of the tolterodine drug.... Agent: SynthonIPInc

20070248669 - Oral sustained release formulation: The present invention relates to an oral sustained release formulation comprising a core, a medicinal layer containing vanlafaxine or a pharmaceutically acceptable salt of venlafaxine and a release-modulating layer containing a release-modulating agent. The present invention also relates to a method for preparing an oral sustained release formulation, and to... Agent: Andrews Kurth LLP

20070248671 - Asymmetric membranes for drug delivery devices: The present invention provides an osmotic dosage form comprising a core containing at least one pharmaceutically active ingredient and which also comprises at least one asymmetric membrane coating wherein said coating comprises one or more substantially water-insoluble polymers, and, one or more solid, water-soluble polymeric materials that do not generate... Agent: Pfizer Inc

20070248672 - Indole and azaindole derivatives with antitumor action: Indole and azaindole compounds useful for the treatment of solid tumours and tumours of the blood are described, they being particularly effective in the treatment of drug resistant tumours; these compounds are also able to synergistically enhance the activity of known antitumour drugs. They can hence be used either alone... Agent: Jay S Cinamon Abelman Frayne And Schwab

20070248675 - Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof: The present invention relates to a nanoparticle-protein-hydrogel composite comprising (1) a polysaccharide-functionalized nanoparticle comprising a core composed of a biodegradable polymer, a hydrogel surface layer composed of a biocompatible polymer emulsifier, and a polysaccharide physically bound to the core and/or the hydrogel layer; (2) a protein forming a specific binding... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070248673 - Copper-based fungicide/bactericide: The present invention discloses an improved copper-based fungicide/bactericide composition. The improved composition offers higher biological activity over typical copper-based products, while requiring significantly less copper in the composition. The present invention also discloses methods of making the improved copper-based fungicide/bactericide composition. The present invention further discloses methods of using the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070248674 - Hydrogel interferon formulations: The present invention is related to pharmaceutical Poloxamer hydrogel formulations containing an interferon. In particular, the invention relates to sustained release hydrogel formulations of interferon-beta, method of preparation and use thereof.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070248676 - Use of nitric oxide adducts: The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be... Agent: Wilmerhale/nitromed

20070248677 - Method for treating warm-blooded vertebrates with a salt of a halide-free glucosamine base and a therapeutic drug: A method of treating a warm-blood vertebrate. The verebrate may be a human being or a lower animal. The treatment method involves administering to the vertebrate in need of such treatment a pharmaceutically effective amount of a salt of a halide-free glucosamine base and a therapeutic drug containing at least... Agent: Law Offices Of Jack Matalon

20070248678 - Uniform-sized hydrophilic metal oxide nanoparticles and preparation method thereof: The present invention provides for a metal oxide nanoparticle that contains a metal core, a shell formed on the surface of the core and consisted of the same metal as the core, and an organic compound containing an element capable of covalently bonding with the nanoparticle and a hydrophilic functional... Agent: Darby & Darby P.C.

20070248679 - Vaccine: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070248680 - Particles for inactivating toxins: The present invention provides for compositions and methods for recognizing toxins in a host. The composition comprising a particle of less than 100 micrometers in diameter having a tag in direct contact with a portion of the particle, the particle comprising a biodegradable polymer and the portion of the particle... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20070248681 - Solid dispersion preparation: Provided are a granule or a tablet of a solid dispersion that allows a drug in a preparation to be rapidly dissolved without impairing the dissolution of the solid dispersion, and a method for producing the same. More specifically, provided are a granule of a solid dispersion comprising a poorly... Agent: Roberts, Mlotkowski & Hobbes

20070248682 - Solid preparation comprising enteric solid dispersion: Provided are a solid preparation comprising an enteric solid dispersion that allows a drug in the preparation to be rapidly dissolved without impairing the dissolution of the solid preparation, and a method for producing the same. More specifically, provided are a solid preparation comprising a poorly soluble drug, an enteric... Agent: Roberts, Mlotkowski & Hobbes

20070248683 - Novel compositions of fat-soluble substances: The invention relates to novel powderous, water-soluble compositions of fat-soluble substances and aqueous solutions or emulsions thereof, wherein the fat-soluble substance(s) are encapsulated as inner (discontinuous) phase within an outer (continuous) phase of a matrix substance.... Agent: Nixon & Vanderhye, PC

20070248686 - Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same: A suspension of vector particles (PV) based on polyamino acids and have a mean hydrodynamic diameter between 30 and 120 nm, and an insulin load factor of from 5 to 25% of associated insulin volume relative to the polyamino acid volume forming the vector particles. The polyamino acids are double-block... Agent: Patton Boggs LLP

20070248685 - Dry hemostatic compositions and methods for their preparation: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has... Agent: Townsend And Townsend And Crew, LLP

20070248684 - Pharmaceutical formulations of oxcarbazepine and methods for its preparation: The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle size distribution, preferably with an enhanced... Agent: Kenyon & Kenyon LLP

20070248687 - Method and composition for modulation of systemic inflammatory responses syndrome (sirs): The present invention relates to pharmaceutical composition comprising animal venom and using same in a method for the treatment of Systemic Inflammatory Response Syndrome (SIRS) and related pathologies.... Agent: Nath & Associates

20070248688 - Animal repellent composition and method: A method is provided including preparing an animal repellent composition and applying it to vegetation. The animal repellent composition may be comprised of mentha piperita (peppermint oil), hydrogenated vegetable oil, garlic oil, white pepper, and gum arabic as a thickener/emulsifier and natural sticking/adherent agent. Additionally, whole or powdered eggs, vinegar... Agent: Mr. Walter J. Teneza Jr.

20070248689 - Copper lowering treatment of inflammatory and fibrotic diseases: The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate and thiotungstate, and to the use of these agents in... Agent: Medlen & Carroll, LLP

20070248690 - Composition and methods for alleviating symptoms of neurotoxicity: A composition for alleviating symptoms associated with neurotoxicity. The composition may comprise compounds for preventing glutamate mediated neurotoxicity. The composition may include one or more of the following elements: at least one glutamate antagonist, at least one cAMP stimulating agent, at least one antioxidant, vitamin B12, at least one transporter... Agent: Kramer & Amado, P.C.

20070248691 - Antibacterial compositions and method of using same: Antibacterial solution useful as a cleaning agent suitable for cutaneous use by humans or otherwise which is aqueous based, free of alcohol and surfactants and having a quaternary ammonium compound as its principal antimicrobial agent, a number of moisturizing agents and DMDM Hydantoin serving at least as a preservative.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070248694 - Anti-inflammatory properties of a standardized extract from euphorbia hirta (pm-251) activity and for treating conditions of inflammation: An organic extract (PM-251) from a plant, Euphorbia hirta (Euphorbaceae) has been standardized. Agronomical standardization has been achieved on this plant by growing it in eastern North Carolina. Subsequently the PM 251 extract has been chemically and biologically standardized. The standardized extract has been tested for its efficacy as an... Agent: Daniels Daniels & Verdonik, P.A.

20070248692 - Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent.... Agent: Banner & Witcoff, Ltd.

20070248693 - Nutraceutical composition and method of use for treatment / prevention of cancer: The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and/or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally... Agent: Elizabeth Mazzio Florida A & M University

20070248695 - Landscaping, plant potting, and horticulture methods according to the traditional oriental or korean medicine: Plants that are substantially utilized as the medicinal ingredients in a selected single prescription of the traditional Oriental and Korean medicine are planted together in close proximity to each other. The plants provide therapeutic effects to the body of a person breathing the fragrance emitted by the plants and observing... Agent: Ladas & Parry LLP

20070248696 - Composition and method for enhancing neuromuscular facilitation and cognitive functions: A composition and a method for improving neuromuscular facilitation, also known as “muscle memory,” and enhancing cognitive functions, such as memory and mental focus. The dietary supplement, and the method for the administration thereof, increases acetylcholine levels, which improves neuromuscular facilitation. In various embodiments, factors other than increasing acetylcholine levels... Agent: Catalina + Associates, LLC

20070248697 - Opthalmic solutions: A method of preventing a lowering of concentration of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α isopropyl ester, the prostaglandin derivative being contained in an ophthalmic solution as an active ingredient. The method including (i) adding to the ophthalmic solution a nonionic surfactant to inhibit the prostaglandin... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070248698 - Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.... Agent: Cantor Colburn, LLP

20070248699 - Pesticides: The invention provides the use of loquat kernel to kill, inactivate or repel pests, in particular nematodes. Also provided is a method of killing, inactivating or repelling nematodes, which method comprises providing loquat kernel and applying the loquat kernel to the nematodes or to an area where the nematodes are... Agent: Leydig Voit & Mayer, Ltd

20070248700 - Extractions and methods comprising elder species: The present invention relates to extracts of elder species plant material prepared by supercritical CO2 extractions methods, methods of treating viruses in a subject and methods of inhibiting viral infections in cells thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070248701 - Methods and formulations for inhibiting naturally occurring phosphodiesterase: Methods and formulations for using Tahitian Noni juice for inhibiting naturally occurring phosphodiesterases (PDEs). The present invention relates to Tahitian Noni juice as a PDE inhibitor to increase body energy and reduce allergy and asthma reactions... Agent: Michael F. Krieger Kirton & Mcconkie

20070248702 - Use of cb2 receptors agonists for the treatment of huntington's disease: The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-α-pinene derivatives, and to pharmaceutical compositions comprising these compounds, and to the use of such compounds for treatment and prevention of the onset of genetic neurodegenerative disorders, in particular Huntington's disease.... Agent: Winston & Strawn LLP Patent Department

20070248704 - Herbal extracts of salicornia species, process of preparation thereof, use thereof against tuberculosis: The present invention relates to novel extracts of Salicornia species. The present invention particularly relates to novel extracts of Salicornia species which show antitubercular activity. The present invention also relates to a process for the preparation of novel extracts of Salicornia species with antitubercular activity and also to the use... Agent: Nixon & Vanderhye, PC

20070248703 - Topical phytotherapeutic compound for the treatment of herpes based on uncaria tomentosa and extraction process for obtaining a vegetal extract from uncaria tomentosa: The present invention concerns a phytotherapic compound for the treatment of herpes based on Uncaria tomentosa characterized by the presence of: (a) A therapeutically efficient amount of an Herbal Extract from Uncaria tomentosa (Willd) DC Rubiaceae, (b) a pharmaceutically acceptable vehicle, (c) at least one pharmaceutically acceptable excipient, and, (d)... Agent: Buchanan, Ingersoll & Rooney PC

20070248705 - Agents for activating the transcription factor nrf2 and foods having such function: A composition, an Nrf2 activating agent, and a food according to the present invention comprise isohumulones or isomerized hop extract as an active ingredient. They are useful in treating, preventing, or ameliorating a disease of condition which is treatable, preventable, or ameliorable by the activation of transcription factor Nrf2. More... Agent: Foley And Lardner LLP Suite 500

20070248706 - Compositions and methods for activating toll-like receptor 4: Methods for activating Toll-like receptor 4 via cholesterol-dependent cytolysins isolated from a Gram-positive bacteria are provided. In addition compositions containing an isolated cholesterol-dependent cytolysin or a fragment thereof or a mimetic of the cytolysin or fragment thereof and methods for use of such composition in inhibiting binding and/or interaction of... Agent: Licata & Tyrrell P.C.

20070243131 - Biopolymer system for tissue sealing: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and... Agent: Schwegman, Lundberg & Woessner, P.A.

20070243153 - Prevention or treatment of male pattern baldness method and device: Method and devices for the prevention or treatment of hair loss, particularly male pattern baldness (MPB), are provided. The pressure on the hair follicles is reduced.... Agent: Brinks Hofer Gilson & Lione

20070243130 - Biopolymer system for tissue sealing: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises an alkylated chitosan, a polybasic carboxylic... Agent: Schwegman, Lundberg & Woessner, P.A.

20070243132 - Transdermal delivery of pharmaceutical agents: The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic molecule or composition. More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject.... Agent: Seed Intellectual Property Law Group PLLC

20070243133 - Method of imaging cell death in vivo: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.... Agent: Lahive & Cockfield, LLP

20070243134 - Receptor selective cannabimimetic aminoalkylindoles: Disclosed are cannabimimetic aminoalkylindole compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. The disclosed compounds may include radioactive atoms. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological... Agent: Alix Yale & Ristas LLP

20070243135 - Method of treating fetal growth retardation and placental ischaemia and insufficiency: A method for treating intrauterine growth retardation in an animal, such as a human being, is disclosed comprising administration of a lysine composition.... Agent: Notaro And Michalos

20070243136 - Methods and compositions for imaging: The present invention is directed to compositions useful as imaging agents for use in MRI, CT, Gamma-scintigraphy, or optical imaging techniques. Methods and compositions of using the same are described.... Agent: Marshall, Gerstein & Borun LLP

20070243139 -